Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "risankizumab"

Updates on PsA: Insights into the Latest Psoriatic Arthritis Treatments & Research

Jason Liebowitz, MD, FACR  |  August 11, 2022

Ana-Maria Orbai, MD, MHS, addressed the latest research into psoriatic arthritis (PsA), including a comprehensive overview of the latest FDA-approved treatments and their implications for clinical practice.

Risankizumab Effective Against Refractory Psoriatic Arthritis

Matthew Phelan  |  January 22, 2022

NEW YORK (Reuters Health)—Risankizumab, an inhibitor of interleukin (IL) 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-3 trial. “Despite the range of available therapies for psoriatic arthritis, efficacious, well-tolerated therapeutic options are needed to treat the diverse…

Risankizumab May Improve Symptoms of PsA

Michele B. Kaufman, PharmD, BCGP  |  January 21, 2021

Results from two recent phase 3 clinical trials show risankizumab significantly improved the skin and joint symptoms of patients with psoriatic arthritis compared with placebo.

Risankizumab & Apremilast Come to Market in Canada

Michele B. Kaufman, PharmD, BCGP  |  March 9, 2020

In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Canada Health has approved apremilast for treating adults with plaque psoriasis and psoriatic arthritis…

Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  February 5, 2020

In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…

Scottish Medicines Consortium Recommends Risankizumab; Plus Real-World Data on Secukinumab

Michele B. Kaufman, PharmD, BCGP  |  November 4, 2019

The Scottish Medicines Consortium has released a detailed advice document recommending risankizumab for treating adults with psoriasis…

Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  April 15, 2019

Japan has approved risankizumab for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults…

Study Results for 9 New Psoriatic Arthritis Drugs

Thomas R. Collins  |  June 21, 2018

CHICAGO—As Eric Ruderman, MD, professor of medicine in rheumatology at Northwestern University Feinberg School of Medicine in Chicago, began his talk on psoriatic arthritis treatment at the ACR State-of-the-Art Clinical Symposium in April, he marveled a bit at how much there was to cover. Drugs gaining prominence in the treatment of rheumatoid arthritis and dermatological…

Risankizumab Promising for Psoriasis; Plus Canada Approves Brodalumab

Michele B. Kaufman, PharmD, BCGP  |  March 21, 2018

Two Phase 3 clinical trials show that risankizumab is effective for achieving skin clearance in patients with psoriasis…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences